Detalhe da pesquisa
1.
Advancing type 2 diabetes therapy with iGlarLixi in older people: Pooled analysis of four randomized controlled trials.
Diabetes Obes Metab
; 26(3): 851-859, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38082473
2.
Effect of delay in treatment intensification in people with type 2 diabetes and suboptimal glycaemia after basal insulin initiation: A real-world observational study.
Diabetes Obes Metab
; 26(2): 512-523, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37857573
3.
iGlarLixi versus premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: The SoliComplex real-world study.
Diabetes Obes Metab
; 25(5): 1249-1260, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36633506
4.
Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study.
Diabetes Spectr
; 36(3): 253-263, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37583559
5.
Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.
Diabetes Obes Metab
; 24(6): 1159-1165, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35257461
6.
Impact of disease duration and ß-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial.
Diabetes Obes Metab
; 22(9): 1567-1576, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32323437
7.
When basal insulin is not enough: A dose-response relationship between insulin glargine 100 units/mL and glycaemic control.
Diabetes Obes Metab
; 21(6): 1305-1310, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30724009
8.
EFFICACY AND SAFETY OF IGLARLIXI IN HISPANICS AND NON-HISPANIC WHITES WITH TYPE 2 DIABETES.
Endocr Pract
; 25(11): 1091-1100, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31241362
9.
Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements.
Diabetes Obes Metab
; 20(11): 2680-2684, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29923361
10.
Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone.
Diabetes Obes Metab
; 20(11): 2690-2694, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29923298
11.
Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials.
Diabetes Obes Metab
; 19(2): 275-283, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27767249
12.
When basal insulin is not enough: response to M Davidson.
Diabetes Obes Metab
; 22(4): 711-712, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31724245
13.
Factors associated with therapeutic inertia in individuals with type 2 diabetes mellitus started on basal insulin.
Diabetes Res Clin Pract
; 203: 110888, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37604284
14.
Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers.
Diabetes Ther
; 14(2): 377-386, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36574199
15.
Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi: A Patient-Level Simulation Study.
Diabetes Ther
; 14(8): 1331-1344, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37289358
16.
Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus.
Diabetes Ther
; 14(12): 2109-2125, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37801225
17.
Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US.
Diabetes Ther
; 13(9): 1659-1670, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35930188
18.
Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist.
J Manag Care Spec Pharm
; 28(9): 958-968, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36001104
19.
Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study.
Diabetes Ther
; 11(11): 2629-2645, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32902774
20.
A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide.
Diabetes Ther
; 10(1): 21-33, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30539523